The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota

Immune agonist antibodies (IAAs) are promising immunotherapies that target co-stimulatory receptors to induce potent anti-tumor immune responses, particularly when combined with checkpoint inhibitors. Unfortunately, their clinical translation is hampered by serious dose-limiting, immune-mediated tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Blake, Stephen J., James, Jane, Ryan, Feargal J., Caparros-Martin, Jose, Eden, Georgina L., Tee, Yee C., Salamon, John R., Benson, Saoirse C., Tumes, Damon J., Sribnaia, Anastasia, Stevens, Natalie E., Finnie, John W., Kobayashi, Hiroki, White, Deborah L., Wesselingh, Steve L., O’Gara, Fergal, Lynn, Miriam A., Lynn, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714857/
https://www.ncbi.nlm.nih.gov/pubmed/35028606
http://dx.doi.org/10.1016/j.xcrm.2021.100464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714857/
https://www.ncbi.nlm.nih.gov/pubmed/35028606
http://dx.doi.org/10.1016/j.xcrm.2021.100464

Ejemplares similares